title: [Esomeprazole based triple therapy for the eradication of helicobacter pylori in patients with non-ulcer dyspepsia].
abstract: OBJECTIVE
  To assess the efficacy of esomeprazole-based triple therapy in the eradication of helicobacter pylori (HP).
  
  
  METHODS
  A descriptive, prospective study was carried out between the months of June and August, 2008, at the Gastroenterology Service of the Cayetano Heredia National Hospital (HNCH) in which patients with non-ulcer dyspepsia infected with HP (diagnosed bya biopsy) were randomized and divided into two groups: the control group was treated with Amoxicillin (1g VO e/12h), Clarithromycin (500 mg VO e/12h) and Omeprazole (20 mg VO e/12h) and the study group received Amoxicillin (1g VO e/12h), Clarithromycin (500 mg VO e/12h) and Esomeprazole (20 mg VO e/12h); both treatments were administered over a period of ten days. Four weeks after the conclusion of the treatment, each group underwent an endoscopic control, including biopsy tests and breath tests to determine the eradication of the HP infection.
  
  
  RESULTS
  A total of 83 patients were included, out of which 42 received triple therapy with Omeprazole (control group) and 41 received triple therapy with Esomeprazole (study group). Five patients of the control group and 7 of the study group were lost in the follow-up stage and 3 patients of the control group and 2 of the study group were excluded due to the lack of a breath test. Out of the 34 patients of the control group, HP was eradicated in 25 of them (73,5%) while out of the 32 patients of the study group, HP was eradicated in 26 (81,2%). The most important adverse effects included: diarrhea, headaches, abdominal pain and constipation.
  
  
  CONCLUSIONS
  Treatment with Esomeprazole showed an eradication rate of 8% greater than treatment with Omeprazole and the percentage of adverse effects was similar in both groups.
authors.affiliation: Gastroenterólogo del Hospital Nacional Cayetano Heredia, Lima, Perú.
authors.forename: R
authors.initials: R
authors.lastname: De los Ríos
authors.forename: L
authors.initials: L
authors.lastname: Pinto J
authors.forename: A
authors.initials: A
authors.lastname: Zegarra
authors.forename: C
authors.initials: C
authors.lastname: García
authors.forename: E
authors.initials: E
authors.lastname: Refulio
authors.forename: A
authors.initials: A
authors.lastname: Piscoya
authors.forename: J
authors.initials: J
authors.lastname: Huerta-Mercado
authors.forename: A
authors.initials: A
authors.lastname: Bussalleu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology*; D064098:Esomeprazole; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole; D064098:Esomeprazole